With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially … Continue Reading Logistics of CAR T-Cell Therapy in Real-World Practice
Adoptive Cell Transfer Method Using RNAi Treatment Cancer immunotherapy has made significant strides in recent years, especially in the development of treatments for solid tumors. Of the several approaches to … Continue Reading Cancer Immunotherapy and RNA Interference Approach Seems to Present a Promising Matchup
Σε επενδύσεις 55 εκατομμυρίων δολαρίων προχωρά η φαρμακευτική επιχείρηση Novartis για την ανέγερση νέας μονάδας παραγωγής στο Durham, της Βόρειας Καρολίνα. Για το νέο εργοστάσιο, στο οποίο η εταιρεία εκτιμά … Continue Reading Επενδύσεις 55 εκατ. για νέα μονάδα και προσλήψεις 200 ατόμων από την Novartis
My name is Karol Sikora, I’m professor of cancer medicine originally at Imperial College London, and now I’ve set up a variety of groups looking at delivery of cancer services. … Continue Reading The Benefits and Challenges of Tumour Immunotherapy
Penn Medicine researchers in Philadelphia may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T-cell therapy, and the … Continue Reading T-Cell Biomarker Predicts CLL Patients’ Response to CAR T-Cell Therapy
Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice. By Vicki Brower Illustration of … Continue Reading New Insights to Improve CAR T Cells’ Safety
CD123 is a subunit of the heterodimeric interleukin-3-receptor (IL-3R) which is widely expressed on human hematologic malignancies including acute myeloid leukemia (AML). In addition, CD123 can be found on the … Continue Reading MB-102
SAN JOSE, Calif. – Although CAR-T therapies have only been approved for the treatment of B-cell blood cancers, tiny ITUS believes it is on track to develop a CAR-T treatment … Continue Reading ITUS Pushes CAR-T Program for Solid Tumors, Develops Early Cancer Detection Platform
The FDA has approved the use of Novartis’ CAR-T therapy Kymriah in adult patients with diffuse large B-cell lymphoma (DLBCL), an indication where it will compete with Gilead’s Yescarta. Kymriah … Continue Reading Novartis and Gilead’s CAR-T Therapies Now Compete for the Same Cancer Patients
Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a … Continue Reading The First CAR-T Therapy Is Not Living Up to Commercial Expectations
Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are … Continue Reading It’s Blood Cancer Day, how is Biotech fixing it?
Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno … Continue Reading What do the CAR-T Patient Deaths Mean for the Future of the Field?